An interventional study of Enhanced (experimental) education and Standard (control) education. in Aneuploidy, Genetic Disease and Pregnancy Related, sponsored by Women and Infants Hospital of Rhode Island. Completed at 1 site in United States. Open to female participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-04.
Sponsored by Women and Infants Hospital of Rhode Island · Not applicable, Interventional, and Other
The investigators propose a randomized controlled trial to assess baseline maternal knowledge of and attitudes toward commercial prenatal genetic testing laboratories' genetic privacy practices, and to determine whether a brief educational intervention alters these attitudes.
The investigators propose a randomized controlled trial to assess baseline maternal knowledge of and attitudes toward commercial prenatal genetic testing laboratories' genetic privacy practices, and to determine whether a brief educational intervention alters these attitudes. Pregnant women undergoing specialized fetal anatomic ultrasound surveys at Women and Infants' maternal fetal medicine prenatal diagnostic imaging centers will be recruited to participate. Volunteers will be randomized to receive either standard education about prenatal genetic testing or standard education plus additional education about federal genetic privacy protections. Next, the participants view the educational materials to which they were randomized. Finally, all volunteers will take the same survey, which will assess baseline demographic variables as well as their knowledge of and attitudes toward broad sharing of data obtained from prenatal genetic testing. Once finished with the survey, volunteers will have completed their participation in this study.
Exclusion Criteria:
The control arm will receive standard education about cell-free DNA screening that would typically be presented during a prenatal visit.
Behavioral: Standard (control) education.
The experimental arm will receive additional education about federal legislation that protects the privacy of genetic information (Genetic Information Nondiscrimination Act, GINA).
Behavioral: Enhanced (experimental) education
See arm description.
See arm description.
Knowledge about broad sharing of genetic data for non-clinical research purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient knowledge about the potential sharing of their genetic data for non-clinical research purposes? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of broad sharing of genetic data for non-clinical research purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of laboratory-initiated sharing of their de-identified genetic data for non-clinical purposes? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of retention of genetic data for non-clinical purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of retaining their de-identified genetic data to potentially use it for non-clinical purposes? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of use of genetic data for non-clinical purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What is patient acceptance of using their de-identified genetic data for non-clinical purposes such as research and development? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Knowledge and understanding of aneuploidy screening and results
Are patients aware that they underwent aneuploidy screening with cell-free fetal DNA (cfDNA)? Are they aware of their results? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Knowledge and understanding of carrier testing and results
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Are patients aware that they underwent carrier testing? Are they aware of their results? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Acceptability of retention, use, and broad sharing of fetal genetic data for non-clinical research purposes
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Assess maternal acceptance of each of these outcomes. Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal rationale for pursuing cfDNA
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: What prompted patient to pursue cfDNA testing? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal knowledge of different commercial cfDNA providers
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: Are patents who have undergone cfDNA testing aware that multiple companies offer this service? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal knowledge pertaining to Down Syndrome and the genetics of trisomies.
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: To what extent do mothers who have undergone cfDNA screening and are participating in this study understand these topics? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Maternal perceptions of the de-identifiability of genetic data
Using a newly designed survey instrument (the Prenatal Testing Opinions Survey), the investigators aim to answer the following question: To what extent do mothers who have undergone cfDNA screening believe that deidentified genetic information is not re-identifiable? Outcome will be measured on the Likert scale.
Time frame: This outcome will be assessed immediately after exposure to education (day 0)
Plan to share: Yes — Non-identifiable data will be freely shared with other researchers upon request for facilitate reproducibility or future systemic review, pending approval from local institutional review board.
This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Women and Infants Hospital of Rhode Island